Latest Intelligence on Pain

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

A blockbuster is born in Johnson & Johnson's Nucynta ER

Johnson & Johnson has received FDA approval for Nucynta ER in moderate to severe chronic pain. Backed by clinical trial data showing comparable efficacy and superior tolerability to the market-leading opioid, OxyContin, Nucynta ER will be a commercial success for Johnson & Johnson. Additional benefits in neuropathic pain will further strengthen the clinical argument for its use.

Published By Datamonitor
30 Aug 2011
Expert View
Expert View

AAN 2011: recent FDA approvals for niche indications provide a positive tone

Datamonitor recently attended the 63rd American Academy of Neurology Annual Meeting in Honolulu, Hawaii, held over April 9-16, 2011. Below are the highlights of the conference's coverage of new drugs for niche neurological indications.

Published By Datamonitor
03 May 2011
CommentWire
CommentWire

Adolor: no pain, large gains

Published By Datamonitor
21 Dec 2000
ResearchWire
ResearchWire

Anticonvulsants: 12% usage rate for US migraine prophylaxis

Published By Datamonitor
31 Jan 2002
ResearchWire
ResearchWire

Anticonvulsants: 12% usage rate for US migraine prophylaxis

Published By Datamonitor
12 Dec 2001
ResearchWire
ResearchWire

Anticonvulsants: diabetic neuropathy is a key market

Published By Datamonitor
22 Jan 2002
Expert View
Expert View

APS 2010: fibromyalgia newcomer seeks differentiation while prospective player draws nearer

Established drugs such as Cymbalta and Lyrica will serve to restrict uptake of the most recent entrant to the fibromyalgia market, Savella. Accordingly, data presented at this year's American Pain Society Annual Meeting indicate that Savella's marketing companies are endeavoring to differentiate the product from its key competitors in order to maintain uptake and drive sales.

Published By Datamonitor
17 May 2010
Expert View
Expert View

APS 2010: opioid safety and tolerability analyses take center stage

Opioid-related announcements at this year's American Pain Society meeting reflected the FDA's current focus on instituting regulations to increase the safety of this class. Johnson & Johnson used the meeting to present long-term data for its advanced candidate tapentadol, while King Pharmaceuticals demonstrated a taper procedure to be successful in minimizing withdrawal in patients taking Embeda.

Published By Datamonitor
17 May 2010
Expert View
Expert View

APS 2011: competition in acute pain is heating up

Datamonitor recently attended the 30th Annual Scientific Meeting of the American Pain Society in Austin, Texas, held over May 19-21, 2011. Below are the highlights of the conference's coverage of rapid-acting opioids in acute pain.

Published By Datamonitor
03 Jun 2011
Expert View
Expert View

APS 2011: Exalgo and tapentadol ER go head-to-head with OxyContin

Datamonitor recently attended the 30th Annual Scientific Meeting of the American Pain Society in Austin, Texas, held over May 19-21, 2011. Below are the highlights of the conference's coverage of long-acting opioids in chronic pain.

Published By Datamonitor
06 Jun 2011

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.